Paper - WANFANG MED ONLINE

You Position: Home > Paper

糖尿病性黄斑水肿的药物治疗进展

( views:658, downloads:1002 )

Author:: No author available

Journal Title:: CHINESE JOURNAL OF OCULAR FUNDUS DISEASES

Issue:: 2

DOI:: 10.3760/cma.j.issn.1005-1015.2010.02.31

Key Word:: 糖尿病视网膜病变/治疗;黄斑水肿/药物疗法;综述文献

Abstract：糖尿病性黄斑水肿(DME)是导致糖尿病视网膜病变(DR)患者视力下降的主要原因之一.目前,激光光凝和玻璃体手术治疗已经明显降低了DR的致盲率,但二者对于改善视力的疗效、特别是对于糖尿病性黄斑水肿的疗效尚不能令人满意.随着对DR发病机制的深入研究,目前已开发出多种药物用于防治DR,特别是在治疗DME方面取得了一定的疗效,包括糖皮质激素,抗血管内皮生长因子药物、非甾体类药物、降血脂药物、血管紧张素抑制剂和选择性蛋白激酶C-β抑制剂.本文就近几年来药物治疗糖尿病性黄斑水肿的进展作一综述.

Reference

[1].Photocoagulation for Diabetic Macular Edema[J].1985.
[2]Ikuo Inoue,Kouta Shino,Satoru Noji,etc.Expression of Peroxisome Proliferator-Activated Receptor α (PPARα) in Primary Cultures of Human Vascular Endothelial Cells[J].1998,246(2).
[3]Tremolada G,Lattanzio R,Mazzolari G,etc.The therapeutic potential of VEGF inhibition in diabetic microvascular complications.[J].2007,7(6).
[4]L P, Aiello,R L, Avery,P G, Arrigg,etc.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.[J].1994,331(22).
[5]Miyamoto K,Tsujikawa A,Ogura Y,etc.In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats.[J].1998,39(11).
[6]Kim JH,Yu YS,Cho CS,etc.Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy.[J].2009,29(3).
[7]UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2\u00a0diabetes: UKPDS 38[J].1998.
[8]Sutter FK,Simpson JM,Gillies MC.Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial.[J].2004,111(11).
[9]George H. Bresnick.Diabetic Macular Edema: A Review[J].1986,93(7).
[10]Davis MD,Vignati L,Zhi XE,etc.Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.[J].2006,113(12).
[11]Mark C, Gillies,Judy M, Simpson,Frank A, Billson,etc.Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial.[J].2004,122(3).
[12]Peters GB 3rd,Liu W,Miller M,etc.Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection.[J].2003,110(4).
[13]Lima C,Yang CH,Guo H,etc.Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device.[J].2000,41(11).
[14]Singerman L.Combination therapy using the small interfering RNA bevasiranib.[J].2009,29(6 Suppl.).
[15]Tsilimbaris MK,Panagiotoglou TD,Charisis SK,etc.The use of intravitreal etanercept in diabetic macular oedema.[J].2007,22(2).
[16].The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus[J].1993.
[17]Bankert JM,Topping TM,Duker JS,etc.A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema.[J].2006,113(10).
[18]ElinorD.U. Powell,RichardA. Field.Diabetic Retinopathy and Rheumatoid Arthritis[J].1964,284(7349).
[19]Theodossiadis PG,Markomichelakis NN,Sfikakis PP.Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation.[J].2007,27(4).
[20]Yasuo Tano,David Chandler,Robert Machemer.Treatment of Intraocular Proliferation with Intravitreal Injection of Triamcinolone Acetonide[J].1980,90(6).
[21]Altaweel M,Patel M,Bressler NM,etc.A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.[J].2005,112(10).
[22]Perruchoud AP,Roth M,Nauck M,etc.Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells.[J].1998,341(2).
[23]Yoshimura N,Hirose F,Miyahara S,etc.Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina.[J].2005,46(4).
[24]Hernandez C,Simo R.Advances in the medical treatment of diabetic retinopathy.[J].2009,32(8).
[25]Shah SM,Yang K,Ingerman A,etc.An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema.[J].2009,93(2).
[26]Marchand-Leroux C,Palmier B,Chen XR,etc.Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury.[J].2007,24(7).
[27]Sander B,Lund Andersen H,Larsen M,etc.Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema.[J].2005,46(10).
[28]Maia M,Arevalo JF,Solis-Vivanco A,etc.Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.[J].2007,114(4).
[29]Nion S,Bouly M,Bordet R,etc.Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment.[J].2003,23(15).
[30]Eguchi K,Hayashi F,Shirato S,etc.Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial.[J].2000,44(1).
[31]Peter van Wijngaarden,Douglas J. Coster,Keryn A. Williams.Inhibitors of Ocular Neovascularization: Promises and Potential Problems[J].2005,293(12).
[32]Greven CM,Scott IU,Edwards AR,etc.A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.[J].2007,114(10).
[33]Summanen PA,Williamson E,Mitchell P,etc.Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.[J].2007,370(9600).
[34]Holash J,Burova E,Huang T,etc.VEGF-Trap: A VEGF blocker with potent antitumor effects.[J].2002,99(17).